Published in Proc Natl Acad Sci U S A on January 29, 2002
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci (2007) 7.77
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 4.52
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci (2008) 2.67
Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron (2009) 2.48
Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci (2008) 2.34
Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann Neurol (2010) 2.17
Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther (2008) 2.14
Human nasal olfactory epithelium as a dynamic marker for CNS therapy development. Exp Neurol (2011) 2.13
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int (2007) 2.11
Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol (2006) 2.00
GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One (2007) 1.99
Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A (2008) 1.84
Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet (2010) 1.81
Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet (2009) 1.79
Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci U S A (2007) 1.79
T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol (2009) 1.78
Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci (2008) 1.72
Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell (2014) 1.65
Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron (2010) 1.65
Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes. J Neuropathol Exp Neurol (2010) 1.64
Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol (2008) 1.61
Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp Neurol (2008) 1.59
Reactive astrocytes secrete lcn2 to promote neuron death. Proc Natl Acad Sci U S A (2013) 1.59
Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron (2015) 1.57
Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet (2003) 1.56
Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp Neurol (2007) 1.56
Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry (2005) 1.55
Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J Neurosci (2013) 1.51
Mutant dynein (Loa) triggers proprioceptive axon loss that extends survival only in the SOD1 ALS model with highest motor neuron death. Proc Natl Acad Sci U S A (2008) 1.45
Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A (2007) 1.42
Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A (2011) 1.38
Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm (2014) 1.35
Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun (2010) 1.34
Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech Ageing Dev (2010) 1.30
D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J (2007) 1.26
Rodent models of TDP-43: recent advances. Brain Res (2012) 1.24
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.21
Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res (2007) 1.20
Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet (2004) 1.20
Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci (2012) 1.19
Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci U S A (2005) 1.19
Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2011) 1.19
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One (2013) 1.19
Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A (2003) 1.18
Decoding ALS: from genes to mechanism. Nature (2016) 1.18
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome (2011) 1.17
Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One (2012) 1.17
Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cell Proteomics (2004) 1.17
Stem cell technology for the study and treatment of motor neuron diseases. Regen Med (2011) 1.16
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.16
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2003) 1.14
Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One (2011) 1.14
Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal (2009) 1.14
The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov (2012) 1.13
Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One (2012) 1.13
Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis. J Neurosci (2009) 1.11
Glial cells in amyotrophic lateral sclerosis. Exp Neurol (2014) 1.11
Axonal mitochondrial clusters containing mutant SOD1 in transgenic models of ALS. Antioxid Redox Signal (2009) 1.11
Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci Lett (2011) 1.10
D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci U S A (2011) 1.10
The inflammatory cytokine, interleukin-1 beta, mediates loss of astroglial glutamate transport and drives excitotoxic motor neuron injury in the spinal cord during acute viral encephalomyelitis. J Neurochem (2008) 1.10
Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J Biol Chem (2013) 1.10
Glial cells in amyotrophic lateral sclerosis. Neurol Res Int (2011) 1.08
Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis. Exp Biol Med (Maywood) (2009) 1.06
Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol Ther (2013) 1.06
Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J (2013) 1.05
The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci (2012) 1.05
Stem cell therapy for the spinal cord. Stem Cell Res Ther (2012) 1.05
Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology (2010) 1.04
The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J (2003) 1.04
Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics (2010) 1.02
Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. Dev Neurobiol (2009) 1.02
Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci (2012) 1.02
Neuronal activity regulates glutamate transporter dynamics in developing astrocytes. Glia (2011) 1.01
Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiol Dis (2010) 1.01
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol (2013) 1.01
Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Exp Neurol (2007) 1.00
Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). PLoS One (2011) 1.00
Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotox Res (2012) 1.00
Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 1.00
Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp Mol Med (2009) 0.99
Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1. J Neurosci Res (2008) 0.98
Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum Mol Genet (2013) 0.96
Ubiquitination-mediated internalization and degradation of the astroglial glutamate transporter, GLT-1. Neurochem Int (2008) 0.95
The Role of the Innate Immune System in ALS. Front Pharmacol (2012) 0.95
Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. Curr Stem Cell Res Ther (2009) 0.95
Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med (2015) 0.95
Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci (2014) 0.95
Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection. Brain (2010) 0.95
Elusive roles for reactive astrocytes in neurodegenerative diseases. Front Cell Neurosci (2015) 0.95
Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model. Neurobiol Dis (2011) 0.94
Modeling Alzheimer's disease in transgenic rats. Mol Neurodegener (2013) 0.93
Motor neuron-immune interactions: the vicious circle of ALS. J Neural Transm (Vienna) (2010) 0.93
Cellular interplay between neurons and glia: toward a comprehensive mechanism for excitotoxic neuronal loss in neurodegeneration. Cellscience (2007) 0.92
Stem cell transplantation for motor neuron disease: current approaches and future perspectives. Neurotherapeutics (2011) 0.92
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 21.65
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron (1997) 6.16
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron (1995) 6.03
Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science (1993) 5.78
Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 5.23
Localization of neuronal and glial glutamate transporters. Neuron (1994) 5.14
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet (1996) 4.77
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med (1992) 3.71
Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol (1995) 3.66
Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2000) 3.11
Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (1995) 2.79
ALS, SOD and peroxynitrite. Nature (1993) 2.64
Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci (2001) 2.51
Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron (1998) 2.45
Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci (2001) 2.43
Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci (2000) 2.27
Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci U S A (1995) 2.12
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A (1996) 2.08
Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. J Neurol Sci (1984) 1.65
Inhibition of ICE slows ALS in mice. Nature (1997) 1.61
A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol (1997) 1.39
Familial motor neuron disease. Evidence for at least three different types. Neurology (1976) 1.34
Regional deafferentation down-regulates subtypes of glutamate transporter proteins. J Neurochem (1995) 1.19
Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol (1998) 1.18
Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathology (2001) 1.14
Molecular biology. Enhancers, chromosome position effects, and transgenic mice. Nature (1984) 1.08
Quantitative immunocytochemical analysis of the spinal cord in G86R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol (1996) 1.05
Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool (1998) 0.97
Presence of Cu/Zn superoxide dismutase (SOD) immunoreactivity in neuronal hyaline inclusions in spinal cords from mice carrying a transgene for Gly93Ala mutant human Cu/Zn SOD. Acta Neuropathol (1998) 0.97
Fimbria-fornix transections selectively down-regulate subtypes of glutamate transporter and glutamate receptor proteins in septum and hippocampus. J Neurochem (1996) 0.95
The genetic and molecular mechanisms of motor neuron disease. Curr Opin Neurobiol (1998) 0.95
ALS-linked Cu/Zn-SOD mutation impairs cerebral synaptic glucose and glutamate transport and exacerbates ischemic brain injury. J Cereb Blood Flow Metab (2000) 0.93
[3H]D-aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study. Brain Res (1994) 0.89
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 9.42
ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron (2006) 7.82
On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer (2005) 7.53
Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci (2004) 6.99
The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol (2006) 6.85
Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol (2009) 6.43
Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell (2006) 6.37
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci (2011) 6.01
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet (2010) 5.75
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature (2012) 4.95
Rethinking ALS: the FUS about TDP-43. Cell (2009) 4.71
Propagation of centromeric chromatin requires exit from mitosis. J Cell Biol (2007) 4.60
Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 4.52
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
A standardized kinesin nomenclature. J Cell Biol (2004) 4.43
Structural determinants for generating centromeric chromatin. Nature (2004) 4.25
Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell (2009) 4.22
A test of climate, sun, and culture relationships from an 1810-year Chinese cave record. Science (2008) 3.94
Does aneuploidy cause cancer? Curr Opin Cell Biol (2006) 3.89
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci (2008) 3.78
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell (2005) 3.69
Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A (2004) 3.69
Dynamics of centromere and kinetochore proteins; implications for checkpoint signaling and silencing. Curr Biol (2004) 3.65
Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron (2013) 3.63
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol (2006) 3.42
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
Unattached kinetochores catalyze production of an anaphase inhibitor that requires a Mad2 template to prime Cdc20 for BubR1 binding. Dev Cell (2009) 3.36
Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron (2002) 3.31
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron (2013) 3.25
Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell (2002) 3.23
Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. J Cell Biol (2003) 3.15
Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci (2002) 3.09
NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron (2010) 3.08
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A (2013) 2.95
Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron (2004) 2.94
Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci (2012) 2.93
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell (2012) 2.83
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
Centromere identity maintained by nucleosomes assembled with histone H3 containing the CENP-A targeting domain. Mol Cell (2007) 2.76
Epigenetic centromere propagation and the nature of CENP-a nucleosomes. Cell (2011) 2.74
Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci (2013) 2.71
Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci (2008) 2.67
ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A (2010) 2.65
Variations in promoter activity reveal a differential expression and physiology of glutamate transporters by glia in the developing and mature CNS. J Neurosci (2007) 2.53
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol (2011) 2.48
Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron (2009) 2.48
Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell (2003) 2.47
Cep152 interacts with Plk4 and is required for centriole duplication. J Cell Biol (2010) 2.45
ZW10 links mitotic checkpoint signaling to the structural kinetochore. J Cell Biol (2005) 2.36
Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci U S A (2008) 2.35
Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet (2006) 2.34
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31
Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med (2003) 2.27
Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 2.25
An epigenetic mark generated by the incorporation of CENP-A into centromeric nucleosomes. Proc Natl Acad Sci U S A (2007) 2.23
An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med (2007) 2.20
Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures. Chem Biol (2007) 2.20
Human nasal olfactory epithelium as a dynamic marker for CNS therapy development. Exp Neurol (2011) 2.13
Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res (2007) 2.12
Microtubule capture by CENP-E silences BubR1-dependent mitotic checkpoint signaling. J Cell Biol (2005) 2.11
Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20. Mol Cell (2013) 2.06
Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J Cell Biol (2010) 2.05
The seeds of neurodegeneration: prion-like spreading in ALS. Cell (2011) 2.03
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J Cell Biol (2003) 2.02
Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest (2007) 2.00
Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E. Cell (2010) 2.00
Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2006) 1.97
Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet (2011) 1.95
CENP-A-containing nucleosomes: easier disassembly versus exclusive centromeric localization. J Mol Biol (2007) 1.93
Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab (2012) 1.92
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2002) 1.87
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A (2008) 1.84
Are electronic health records ready for genomic medicine? Genet Med (2009) 1.82
High-throughput microarray detection of olfactory receptor gene expression in the mouse. Proc Natl Acad Sci U S A (2004) 1.82
Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep (2012) 1.81
Limb ischemic preconditioning reduces heart and lung injury after an open heart operation in infants. Pediatr Cardiol (2009) 1.81
Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg (2015) 1.80
Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci U S A (2007) 1.79
Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem (2002) 1.78
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke (2004) 1.78
CENP-E combines a slow, processive motor and a flexible coiled coil to produce an essential motile kinetochore tether. J Cell Biol (2008) 1.77
Northern Hemisphere summer monsoon intensified by mega-El Nino/southern oscillation and Atlantic multidecadal oscillation. Proc Natl Acad Sci U S A (2013) 1.75
Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. J Biol Chem (2002) 1.74